[1]
|
Azevedo, C. and Saiardi A. (2016) Why Always Lysine? The Ongoing Tale of One of the Most Modified Amino Acids. Advances in Biological Regulation, 60, 144-150. https://doi.org/10.1016/j.jbior.2015.09.008
|
[2]
|
Xu, H., Zhou, J. and Lin, S. (2017) PLMD: An Updated Data Resource of Protein Lysine Modifications. Journal of Genetics and Ge-nomics, 44, 243-250. https://doi.org/10.1016/j.jgg.2017.03.007
|
[3]
|
Ganesan, A. (2018) Epigenetic Drug Discov-ery: A Success Story for Cofactor Interference. Philosophical Transactions of the Royal Society B: Biological Sciences, 373, Article ID: 20170069. https://doi.org/10.1098/rstb.2017.0069
|
[4]
|
Yoshida, M., Kudo, N. and Kosono, S. (2017) Chemical and Structural Biology of Protein Lysine Deacetylases. Proceedings of the Japan Academy, Series B, 93, 297-321. https://doi.org/10.2183/pjab.93.019
|
[5]
|
Jiang, Y., Liu, J. and Chen, D. (2017) Sirtuin Inhibition: Strate-gies, Inhibitors and Therapeutic Potential. Trends in Pharmacological Sciences, 38, 459-472. https://doi.org/10.1016/j.tips.2017.01.009
|
[6]
|
Yoshida, M., Kijima, M. and Akita, M. (1990) Potent and Specific Inhibition of Mammalian Histone Deacetylase both in Vivo and in Vitro by Trichostatina. Journal of Biological Chemistry, 265, 17174-17179.
https://doi.org/10.1016/S0021-9258(17)44885-X
|
[7]
|
Ganesan, A. (2016) Romidepsin and the Zinc-Binding Thiol Family of Natural Product HDAC Inhibitors. In: Fischer, J. and Childers, W.E., Eds., Successful Drug Discovery, Wiley, Hoboken, 13-29.
https://doi.org/10.1002/9783527800315.ch2
|
[8]
|
Jing, Q., Hu, X., Ma, Y., et al. (2019) Marine-Derived Natural Lead Compound Disulfide-Linked Dimer Psammaplin A: Biological Activity and Structural Modification. Marine Drugs, 17, Article 384.
https://doi.org/10.3390/md17070384
|
[9]
|
Wen, S., Carey, K.L., Nakao, Y., Fusetani, N., Packham, G. and Gane-san, A. (2007) Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deacetylase Inhibitors and Design of a More Potent Analogue. Organic Letters, 9, 1105-1108. https://doi.org/10.1021/ol070046y
|
[10]
|
Wang, Y. and Wang, H. (2022) The Emerging Role of Histone Deacetylase 1 in Allergic Diseases. Frontiers in Immunology, 13, Article 1027403. https://doi.org/10.3389/fimmu.2022.1027403
|
[11]
|
Roizman, B. (2011) The Checkpoints of Viral Gene Expression in Productive and Latent Infection: The Role of the HDAC/CoREST/LSD1/REST Repressor Complex. Journal of Virology, 85, 7474-7482.
https://doi.org/10.1128/JVI.00180-11
|
[12]
|
Zhang, H., Ji, L., Yang, Y., Zhang, X., Gang, Y. and Bai, L. (2020) The Role of HDACs and HDACi in Cartilage and Osteoarthritis. Frontiers in Cell and Developmental Biology, 8, Article 560117.
https://doi.org/10.3389/fcell.2020.560117
|
[13]
|
Weïwer, M., Lewis, M.C., Wagner, F.F. and Holson, E.B. (2013) Therapeutic Potential of Isoform Selective HDAC Inhibitors for the Treatment of Schizophrenia. Future Medicinal Chemistry, 5, 1491-1508.
https://doi.org/10.4155/fmc.13.141
|
[14]
|
Kim, J.Y., Cho, H., Yoo, J., et al. (2022) Pathological Role of HDAC8: Cancer and Beyond. Cells, 11, Article 3161.
https://doi.org/10.3390/cells11193161
|
[15]
|
Fontana, A., Cursaro, I., Carullo, G., Gemma, S., Butini, S. and Cam-piani, G. (2022) A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors. In-ternational Journal of Molecular Sciences, 23, Article 10014. https://doi.org/10.3390/ijms231710014
|
[16]
|
Wu, Y., Hou, F., Wang, X., Kong, Q., Han, X. and Bai, B. (2016) Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target. Frontiers in Molecular Neuroscience, 9, Article 00114. https://doi.org/10.3389/fnmol.2016.00114
|
[17]
|
Mielcarek, M., zielonka, D., Carnemolla, A., et al. (2015) HDAC4 as a Potential Therapeutic Target in Neurodegenerative Diseases: A Summary of Recent Achievements. Frontiers in Cel-lular Neuroscience, 9, Article 00042.
https://doi.org/10.3389/fncel.2015.00042
|
[18]
|
Mathias, R.A., Guise, A.J. and Cristea, I.M. (2015) Post-Translational Modifications Regulate Class IIa Histone Deacetylase (HDAC) Function in Health and Disease. Mo-lecular & Cellular Proteomics, 14, 456-470.
https://doi.org/10.1074/mcp.O114.046565
|
[19]
|
Wang, Y., Abrol, R., Mak, J.Y.W., et al. (2022) Histone Deacety-lase 7: A Signalling Hub Controlling Development, Inflammation, Metabolism and Disease. The FEBS Journal, Article ID: 16437. https://doi.org/10.1111/febs.16437
|
[20]
|
Hu, S., Cho, E.-H. and Lee, J.-Y. (2020) Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases. Diabetes & Metabolism Journal, 44, 234-244. https://doi.org/10.4093/dmj.2019.0243
|
[21]
|
Seidel, C., Schnekenburger, M., Dicato, M. and Diederich, M. (2015) Histone Deacetylase 6 in Health and Disease. Epigenomics, 7, 103-118. https://doi.org/10.2217/epi.14.69
|
[22]
|
Pulya, S., Amin, S.A. and Adhikari, N. (2021) HDAC6 as Privileged Target in Drug Discovery: A Perspective. Pharmacological Research, 163, Article ID: 105274. https://doi.org/10.1016/j.phrs.2020.105274
|
[23]
|
Cheng, F., Zheng, B., Wang, J., et al. (2021) Histone Deacetylase 10, a Potential Epigenetic Target for therapy. Bioscience Reports, 41. https://doi.org/10.1042/BSR20210462
|
[24]
|
Liu, S.S., Wu, F. and Jin, Y.M. (2020) HDAC11: A Rising Star in Epigenetics. Biomedicine & Pharmacotherapy, 131, Article ID: 110607. https://doi.org/10.1016/j.biopha.2020.110607
|
[25]
|
Chen, H., Xie, C., Chen, Q. and Zhuang, S. (2022) HDAC11, an Emerging Therapeutic Target for Metabolic Disorders. Frontiers in Endocrinology, 13, Article 989305. https://doi.org/10.3389/fendo.2022.989305
|
[26]
|
Marks, P.A. and Breslow, R. (2007) Dimethyl Sulfoxide to Vori-nostat: Development of this Histone Deacetylase Inhibitor as an Anticancer Drug. Nature Biotechnology, 25, 84-90. https://doi.org/10.1038/nbt1272
|
[27]
|
Ossenkoppele, G.J., Lowenberg, B., Zachee, P., et al. (2013) A Phase I First-in-Human Study with Tefinostat—A Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor—In Patients with Advanced Haematological Malignancies. British Journal of Haematology, 162, 191-201. https://doi.org/10.1111/bjh.12359
|
[28]
|
Jung, D.E., Park, S.B., Kim, K., Kim, C. and Song, S.Y. (2017) CG200745, an HDAC Inhibitor, Induces Anti-Tumour Effects in Cholangiocarcinoma Cell Lines via miRNAs Targeting the Hippo Pathway. Scientific Reports, 7, Article No. 10921. https://doi.org/10.1038/s41598-017-11094-3
|
[29]
|
Santo, L., Hideshima, T., Kung, A.L., et al. (2012) Preclinical Activity, Pharmacodynamic, and Pharmacokinetic Properties of a Se-lective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. Blood, 119, 2579-2589. https://doi.org/10.1182/blood-2011-10-387365
|
[30]
|
Huang, P., Almeciga-Pinto, I., Jarpe, M., et al. (2017) Selec-tive HDAC Inhibition by ACY-241 Enhances the Activity of Paclitaxel in Solid Tumor Models. Oncotarget, 8, 2694-2707. https://doi.org/10.18632/oncotarget.13738
|
[31]
|
Cai, X., Zhai, H.X., Wang, J., et al. (2010) Discovery of 7-(4-(3-Ethynylphenylamino)-7-Methoxyquinazolin- 6-Yloxy)-N-Hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR and HER2 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 53, 2000-2009. https://doi.org/10.1021/jm901453q
|
[32]
|
Mehrling, T. and Chen, Y. (2015) The Alkylating-HDAC In-hibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. An-ti-Cancer Agents in Medicinal Chemistry, 16, 20-28.
https://doi.org/10.2174/1871520615666150518092027
|
[33]
|
Finn, P.W., Loza, E. and Carstensen, E. (2016) The Discovery and Development of Belinostat. In: Fischer, J. and Childers, W.E., Eds., Successful Drug Discovery, Wiley, Hoboken, 31-57. https://doi.org/10.1002/9783527800315.ch3
|
[34]
|
Atadja, P. and Perez, L. (2016) Discovery and Development of Farydak (NVP-LBH589, Panobinostat) as an Anticancer Drug. In: Fischer, J. and Childers, W.E., Eds., Successful Drug Discovery, Wiley, Hoboken, 59-88.
https://doi.org/10.1002/9783527800315.ch4
|
[35]
|
Wang, H., Yu, N., Chen, D., et al. (2011) Discovery of (2E)-3-{2-Butyl-1-[2-(Diethylamino)Ethyl]-1H-Benzimidazol- 5-yl}-N-Hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile. Journal of Medicinal Chemistry, 54, 4694-4720. https://doi.org/10.1021/jm2003552
|
[36]
|
Matalon, S., Palmer, B.E., Nold, M.F., et al. (2010) The Histone Deacety-lase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Supe-rior to Valproic Acid for Latent HIV-1 Expression in Vitro. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 54, 1-9.
https://doi.org/10.1097/QAI.0b013e3181d3dca3
|
[37]
|
Buggy, J.J., Cao, Z.A., Bass, K.E., et al. (2006) CRA-024781: A Novel Synthetic Inhibitor of Histone Deacetylase Enzymes with Antitumor Activity in Vitro and in Vivo. Molecular Cancer Therapeutics, 5, 1309-1317.
https://doi.org/10.1158/1535-7163.MCT-05-0442
|
[38]
|
Lu, Q., Wang, D.S., Chen, C.S., et al. (2005) Struc-ture-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 48, 5530-5535. https://doi.org/10.1021/jm0503749
|
[39]
|
Zhang, S.W., Gong, C.J., Su, M.B., et al. (2020) Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 63, 804-815.
https://doi.org/10.1021/acs.jmedchem.9b01792
|
[40]
|
Arts, J., King, P., Marin, A., et al. (2009) JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer Research, 15, 6841-6851.
https://doi.org/10.1158/1078-0432.CCR-09-0547
|
[41]
|
Moffat, D., Patel, S., Day, F., et al. (2010) Discovery of 2-(6-{[(6-Fluoroquinolin-2-yl)Methyl]Amino}Bicyclo[3.1.0]Hex- 3-yl)-N-Hydroxypyrimidine-5-Carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 53, 8663-8678. https://doi.org/10.1158/1078-0432.CCR-09-0547
|
[42]
|
Qian, C., Lai, C.J., Bao, R., et al. (2012) Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinosi-tol 3-Kinase Signaling. Clinical Cancer Research, 18, 4104-4113.
https://doi.org/10.1158/1078-0432.CCR-12-0055
|
[43]
|
Moradei, O.M., Mallais, T.C., Frechette, S., et al. (2007) Novel Aminophenyl Benzamide-Type Histone Deacetylase Inhibitors with Enhanced Potency and Selectivity. Journal of Medicinal Chemistry, 50, 5543-5546.
https://doi.org/10.1021/jm701079h
|
[44]
|
Khan, N., Jeffers, M., Kumar, S., et al. (2008) Determination of the Class and Isoform Selectivity of Small-Molecule Histone Deacetylase Inhibitors. Biochemical Journal, 409, 581-589. https://doi.org/10.1042/BJ20070779
|
[45]
|
Fournel, M., Bonfils, C., Hou, Y., et al. (2008) MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, has Broad Spectrum Antitumor Activity in Vitro and in Vivo. Molecular Cancer Therapeutics, 7, 759-768.
https://doi.org/10.1158/1535-7163.MCT-07-2026
|
[46]
|
Lu, X., Ning, Z., Li, Z., Cao, H. and Wang, X. (2016) De-velopment of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China. Intractable & Ra-re Diseases Research, 5, 185-191.
https://doi.org/10.5582/irdr.2016.01024
|
[47]
|
Bretz, A.C., Parnitzke, U., Kronthaler, K., et al. (2019) Domatinostat Favors the Immunotherapy Response by Modulating the Tumor Immune Microenvironment (TIME). Journal for Immu-noTherapy of Cancer, 7, 294.
https://doi.org/10.1186/s40425-019-0745-3
|
[48]
|
Eyre, T.A., Collins, G.P., Gupta, A., et al. (2019) A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer: Pharma-cokinetics of CXD101 in Patients with Advanced Cancer. Cancer, 125, 99-108. https://doi.org/10.1002/cncr.31791
|
[49]
|
Zhang, Q., Dai, Y., Cai, Z. and Mou, L. (2018) HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect, 3, 176-187. https://doi.org/10.1002/slct.201702295
|
[50]
|
Suraweera, A., O’Byrne, K.J. and Richard, D.J. (2018) Combination Therapy with Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Po-tential of HDACi. Frontiers in Oncology, 8, Article 92. https://doi.org/10.3389/fonc.2018.00092
|
[51]
|
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G. and Postel-Vinay, S. (2020) Combining Epigenetic Drugs with Other Therapies for Solid Tumours—Past Lessons and Future Promise. Nature Reviews Clinical Oncology, 17, 91-107.
https://doi.org/10.1038/s41571-019-0267-4
|